Press coverage about Alexion Pharmaceuticals (NASDAQ:ALXN) has trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Alexion Pharmaceuticals earned a news impact score of 0.06 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.4296539729872 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:

Shares of Alexion Pharmaceuticals (ALXN) opened at 141.30 on Friday. The firm has a market capitalization of $31.54 billion, a PE ratio of 61.27 and a beta of 1.39. The company’s 50-day moving average price is $141.26 and its 200 day moving average price is $126.29. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The business had revenue of $912.00 million during the quarter, compared to analyst estimates of $846.15 million. During the same period in the prior year, the company earned $1.13 earnings per share. Alexion Pharmaceuticals’s revenue was up 21.1% compared to the same quarter last year. On average, equities analysts forecast that Alexion Pharmaceuticals will post $5.60 earnings per share for the current year.

A number of research analysts recently issued reports on ALXN shares. TheStreet upgraded Alexion Pharmaceuticals from a “c” rating to a “b-” rating in a report on Friday, July 14th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $142.00 price objective on shares of Alexion Pharmaceuticals in a report on Friday, June 9th. SunTrust Banks, Inc. reiterated a “buy” rating and set a $165.00 price objective on shares of Alexion Pharmaceuticals in a report on Friday, July 14th. UBS AG reiterated a “buy” rating and set a $142.00 price objective (up from $140.00) on shares of Alexion Pharmaceuticals in a report on Monday, June 26th. Finally, Credit Suisse Group AG set a $164.00 price objective on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, June 14th. Six research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $154.56.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Alexion Pharmaceuticals (ALXN) Share Price” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/10/07/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-alexion-pharmaceuticals-alxn-share-price.html.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 835 shares of the stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the transaction, the director now directly owns 5,480 shares of the company’s stock, valued at $799,038.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Ann M. Veneman sold 700 shares of the stock in a transaction on Monday, July 31st. The shares were sold at an average price of $137.74, for a total value of $96,418.00. Following the transaction, the director now directly owns 6,315 shares of the company’s stock, valued at $869,828.10. The disclosure for this sale can be found here. Over the last three months, insiders have sold 17,190 shares of company stock valued at $2,433,669. 4.35% of the stock is owned by corporate insiders.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.